# Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy

> **NCT05276284** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kristoffer Rohrberg** · enrollment: 18 (actual)

## Conditions studied

- Solid Tumor, Adult
- Metastatic Cancer

## Interventions

- **COMBINATION_PRODUCT:** Atezolizumab, 6-mercaptopurine, 6-thioguanine

## Key facts

- **NCT ID:** NCT05276284
- **Lead sponsor:** Kristoffer Rohrberg
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-09-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05276284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05276284, "Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05276284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*